Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Clin Genitourin Cancer. 2020 Apr 20;18(5):361–366. doi: 10.1016/j.clgc.2020.04.002

Figure 2.

Figure 2.

A. Patient #4 pre-treatment CT abdomen/pelvis demonstrating large right renal mass. B. Significant interval reduction in the size of the primary renal mass after three cycles of ipilimumab/nivolumab combination therapy followed by pembrolizumab/axitinib for 13 cycles.